Answers are grounded in this paper and cite their sources.
Multicenter trial assesses bioavailability of LCP-Tac compared with PR-Tac in renal transplantation, indicating potential improvements in patient adherence.
Graft rejection and chronic CNI toxicity reduce kidney transplantation success. Oral formulations of tacrolimus such as IR-Tac (immediate release; twice-daily capsules) and PR-Tac (prolonged release; once-daily capsules), exhibit limitations in terms of pharmacokinetics and tolerability, related in part to suboptimal bioavailability. PR-Tac was developed to improve patient adherence to medication and thereby reduce the risk of graft rejection. However, higher drug dosing was seen to be necessary to maintain IR-Tac-equivalent exposure.
No takes yet. Share an insight, caveat, or question.
Banas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: